Condition

Human Immunodeficiency Virus Infections

ClinicalTrials.gov condition label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 11 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials11
Recruiting0
Common interventions16
Lead sponsors shown8
Advertisement

Clinical trials

11 shown
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) InfectionNCT03563742 · 2018-09-24
TERMINATED
Safety, PK and PD Study of ABX464 in Untreated HIV PatientsNCT02452242 · 2015-01-01
COMPLETED
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRTNCT00727597 · 2008-07-01
COMPLETED
Attitudes and Beliefs and the Steps of HIV CareNCT00749840 · 2008-04-01
COMPLETED
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected SubjectsNCT00358917 · 2006-08-01
COMPLETED
Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis TreatmentNCT00332306 · 2006-06-01
UNKNOWN
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected SubjectsNCT00262522 · 2005-11-01
COMPLETED
Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) CapsidNCT00888446 · 2005-10-01
COMPLETED
An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution SyndromeNCT00294918 · 2001-09-01
COMPLETED
Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)NCT00294164 · 2001-03-01
COMPLETED
Short Course Intermittent Regimens for the Treatment of HIV-Associated TuberculosisNCT00376012 · 2001-02-01
UNKNOWN

Common interventions

Mapped drugs appearing in these trials

Shared trial participation only; not evidence of efficacy or approval.

Trial status mix

COMPLETED8
UNKNOWN2
TERMINATED1

Phase mix

PHASE38
PHASE24
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.